Thomas Tull-backed At One Ventures, a venture capital firm, led a $60m Series A funding round in Colossal Biosciences, a biotechnology company, with participation from Animoca Brands, Breyer Capital, Animal Capital, Bold Capital, First Light Capital Group, Boost VC, Jazz Ventures, Builders VC, Green Sands Equity and Draper Associates. “We’re making the path to de-extinction and species preservation a reality by bringing the planet one step closer to reversing the downward trend of ecosystem degradation and the staggering loss of biodiversity through cutting edge genetic tools,” Ben Lamm, Colossal Biosciences Co-Founder and CEO.